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Philipp Latzin, MD, PhD,c,d and Markus Hilty, PhDa,f Bern, Basel, and Zurich, SwitzerlandBackground: Understanding the composition and dynamics of
the upper respiratory tract microbiota in healthy infants is a
prerequisite to investigate the role of the microbiota in patients
with respiratory diseases. This is especially true in early life,
when the immune system is in development.
Objective: We sought to describe the dynamics of the upper
respiratory tract microbiota in healthy infants within the first
year of life.
Methods: After exclusion of low-quality samples, microbiota
characterization was performed by using 16S rDNA
pyrosequencing of 872 nasal swabs collected biweekly from 47
unselected infants.
Results: Bacterial density increased and diversity decreased
within the first year of life (R2 5 0.95 and 0.73, respectively).
A distinct profile for the first 3 months of life was found with
increased relative abundances of Staphlyococcaceae and
Corynebacteriaceae (exponential decay: R2 5 0.94 and 0.96,
respectively). In addition, relative bacterial abundance and
composition differed significantly from summer to winter
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http://dx.doi.org/10.1016/j.jaci.2014.12.1909with increasing time intervals between samples and was best
modeled by an exponential function (R2 5 0.97). Within-subject
dissimilarity in a 2-week time interval was consistently lower than
that between subjects, indicating a personalized microbiota.
Conclusion: This study reveals age and seasonality as major
factors driving the composition of the nasal microbiota within the
first year of life. A subject’s microbiota is personalized but
dynamic throughout the first year. These data are indispensable to
interpretation of cross-sectional studies and investigation of the
role of the microbiota in both healthy subjects and patients with
respiratory diseases. Theymight also serve as a baseline for future
intervention studies. (J Allergy Clin Immunol 2015;135:905-12.)
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The prevalence and incidence of asthma in children continue to
increase, leading to efforts to curb the so-called epidemic, even
while its causes remain ambiguous.1 An association between
bacterial colonization of the airways in children and later
development of asthma has been suggested, particularly for the
potentially pathogenic Streptococcus pneumoniae, Moraxella
catarrhalis, and Haemophilus influenzae.2 However, exposure
to a wider range of microbes seems to have a protective effect
on the development of asthma in children by activating the innate
immune system.3 This finding would support the hygiene
hypothesis, according to which asthma is partly caused by a
lack of microbial exposure early in life and its subsequent
influence on the developing immune system.4 Indeed, the
presence of commensal bacteria was shown to be critical in the
control of allergic airway inflammation in a mouse model.5,6
Therefore it is assumed that the respiratory tract microbiota plays
a crucial role in immune development early in life. In particular,
the ages between early infancy and 3 years are suggested to be
important for the long-term development of immune responses
and asthmatic airway disease. Therefore the best possibility for
intervention to change the natural trajectory of the disease exists
within this window of time.7
In recent studies the respiratory tracts of healthy adult subjects
were found to harbor a homogeneous microbiota that decreases in
biomass from the upper to the lower respiratory tract. The bacteria
present in the lungs were suggested to originate from the upper
respiratory tractmicrobiota throughmicroaspiration.8,9 Therefore
the upper respiratory tract is considered the entry point of
commensals and potential pathogens into the airways. The
nasopharynx was described as an ecologic reservoir consisting
of a broad variety of commensal bacteria and potential
pathogens.10 Recent studies revealed a complex and highly
variable nasopharyngeal microbiota in children,11,12 which905
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antimicrobials, and vaccination.13,14 Despite these significant
findings, a detailed description of the nasopharyngeal microbiota
in healthy children was not previously available.
Previous studies assumed an association between the early
composition of the upper airway microbiota as a marker for later
immune development and subsequent development of allergy and
asthma.2 However, before any conclusions regarding the role of
the microbiota on later asthma and other respiratory diseases
can be drawn, this hypothesis must be tested in longitudinal
measurements.
The aim of this study was to analyze biweekly serial dynamics
of the nasal microbiota in healthy infants within the first year of
life. In particular, we revealed the influence of age and seasonality
on the personalized composition of the microbiota and
investigated its dissimilarity throughout the first year of life.METHODS
Study design
A total of 48 healthy infants from the prospective Basel Bern Infant Lung
Development cohort (www.birthcohorts.net) study15 were enrolled and
followedweekly within their first year of life. Pregnant mothers were recruited
from the 4 major maternity hospitals and practices of obstetricians in the
agglomeration of Bern, Switzerland, through advertisements and interviews.
Exclusion criteria for the study were as follows: ethnicity other than white,
preterm delivery (<37 weeks’ gestation), major birth defects, disease or later
diagnosis of airway malformation, or specific chronic respiratory disease. The
study was approved by the Ethics Committee of the Canton of Bern.Nasal swab procedure
Nasal swabs (Verridial E. Mueller, Blonay, Switzerland) were collected
biweekly by the parents of the study infants, starting in the fifth week of life.
Parents were personally instructed by the study nurses on how to obtain the
nasal samples in a standardized way. Immediately after acquisition, nasal
swabs were sent in transport tubes and medium (UTM tubes, Verridial E.
Muller) to the study center and frozen at 2808C within 10 days or less. In
addition, study nurses made weekly telephone calls, during which study
parents were interviewed by using a standardized questionnaire. The study
infant’s health status, as well as respiratory symptoms and antibiotic therapy,
were assessed.16 Nasal swabs taken during upper or lower respiratory tract
infection or while the infant received antibiotic therapy were excluded from
the analysis because the goal of the present study was to analyze swabs of
clinically healthy infants at the time of sampling.PCR amplification of 16S ribosomal RNA genes and
454 amplicon sequencing
Amplification by using PCR and amplicon sequencing was described
elsewhere.13 In brief, DNA was extracted with 200 mL of transport medium,
followed by amplification of the bacterial 16S ribosomal RNA (rRNA)
variable regions V3 to V5 by using the multiplex identifier tagged primer pair
341F/907R. PCR reactions were eluted by 40 mL of double-distilled water,
and the concentrationwasmeasuredwith theAgilent 2100Bioanalyzer (Agilent
Technologies, Basel, Switzerland). PCR products with a concentration of less
than 1.0 ng/mL were excluded from the study. This corresponds to less than 1pg/mL bacterial DNA, as evaluated by using quantitative PCR of pneumococcal
DNA at different dilutions (data not shown). A minimum of 1 pg/mL bacterial
DNA was recently recommended as the threshold when working with
low-density materials.17 Of each purified PCR product, 40 ng/mL was pooled,
whereas every multiplex identifier was used once, resulting in 8 amplicon
pools.13 The amplicon pools were sequenced with the 454 sequencing platform.
The reads were submitted to the National Center for Biotechnology Information
Sequence Read Archive (accession no. SRP041616). Analysis of sequencing
products was performed by using PyroTagger, which comprises the definition
of operational taxonomic units based on 97% sequencing identity, estimation
of chimeras, and taxonomic assignments.18
Quality control
In addition to the exclusion of PCR products with a concentration of less
than 1 ng/mL, we performed the following quality control steps. First, a cutoff
value of 70 reads per sample was defined. Second, 2 negative control samples
were sequenced, and those samples displaying greater than 5% sequence reads
identical to these negative control samples were excluded.
Bacterial density and a diversity calculations
Bacterial density was estimated based on the concentration of the PCR
product. a Diversity, which was referred to as within-community diversity,19
was assessed by using the Shannon Diversity Index (SDI). The SDI was
calculated in R, version 3.02 (http://www.R-project.org.), by using the
function ‘‘diversity’’ of the ‘‘vegan’’ package. For analyses of bacterial density
and SDI, samples were binned according to the date of acquisition, either
referring to the month of the year or to the age of the study infant, resulting
in 1 to 3 samples per infant for every month.
b Diversity analyses
bDiversity, which is referred to as community comparison,19 was calculated
by using the function ‘‘vegdist’’ of the ‘‘vegan’’ package in R. We used the
Manhattan-type dissimilarity Jaccard to calculate the weighted beta diversity
indices (abundance-based). For each study infant, Jaccard dissimilarity was
calculated by means of pairwise comparison of 2 samples. Time intervals (Dt)
between the samples were subsequently increased, ranging from 2 to 44 weeks.
Values from each infant were binned according to the time interval between the
samples, as previously described.20 Short-term within-subject dissimilarity
includes all pairwise comparisons of samples from a subject in 2-week intervals.
Resulting values were grouped according to the month of age or season.
Between-subject dissimilarity includes pairwise comparisons of all samples
from1 subjectwith all samples fromall the other subjectswithin the correspond-
ing month. ‘‘metaMDS’’ of the ‘‘vegan’’ package was used for nonmetric
multidimensional scaling (nMDS), as previously described.13 As an input
matrix, we used the abundance-based Jaccard dissimilarities, as described
above. Statistical analysis on nMDS clustering was done with the function
‘‘adonis’’ of the ‘‘vegan’’ package. Vectors were fitted by using ‘‘envfit’’: the
resulting arrows point to the direction of the most rapid change in the variable,
whereas the length indicates the strength of this gradient.21 Age in months and
month of sampling (seasonality) was investigated for clustering.
Calculation of relative bacterial abundances
Prevalence and relative abundances of bacterial families were obtained
based on the taxonomic assignment of PyroTagger, as described
previously.13,18 For every bacterial family, the mean and 95% CI per sample
were calculated. The 5 most abundant families were analyzed separately,
whereas all the remaining families were grouped as ‘‘others.’’ Again, samples
were binned according to the date of acquisition, either referring to the month
of the year or to the age of the study infant.Additional statistical analyses
Regression models were then fitted for the relative bacterial abundance,
bacterial density, SDI value, and b diversity by using either a linear or an
exponential function for age and a second-order polynomial function for the
FIG 1. Flow chart of study infants and nasal swab processing, including information on excluded samples.
Infections were defined as upper or lower respiratory tract infections. *Twenty-one of 134 excluded nasal
swabs were obtained from 1 study infant and therefore samples from that infant were fully excluded from
the study, resulting in 47 infants included.
TABLE I. Characteristics of the study population (n 5 48
infants)
Characteristic Summary statistic
Anthropometrics
Boys, no. (%) 24 (50.0)
Gestational age at birth (wk), mean (SD) 39.7 (1.6)
Length at birth (cm), mean (SD) 49.8 (2.0)
Birth weight (kg), mean (SD) 3.4 (0.5)
Diet
Breast-feeding,* no. (%) 48 (100.0)
Pneumococcal vaccine
First dose: weeks after birth, mean (SD) 10.1 (3.5)
Second dose: weeks after birth, mean (SD) 18.9 (4.1)
Season of birth
Spring, no. (%) 12 (25.0)
Summer, no. (%) 13 (27.1)
Fall, no. (%) 12 (25.0)
Winter, no. (%) 11 (22.9)
Sampling
Nasal swabs included, mean per infant (SD) 18.6 (3.1)
*Infants were breast-fed for a mean 6 SD duration of 8.9 6 2.6 months.
Value for the first dose represents the mean number of weeks for 42 infants. Six
infants did not receive any dose. The second dose was received by 41 infants. None of
the study infants received the third dose before the 12th month of life. Detailed
information is available in Table E1.
Mean and SD of 47 infants.
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GraphPad Prism software (version 6.03; GraphPad Software, La Jolla, Calif).
The model with the best goodness of fit (R2) was chosen and interpreted as
accurate if the R2 value was greater than 0.4.
Analyses were repeated with a different multivariable linear regression
model to evaluate robustness and to assess whether age and season were
independently associated with outcomes. A multilevel model with a random
effect to correct for clustering on the individual level was used. Outcome
parameters were bacterial density, SDI value, and the relative abundance of the
5 most abundant bacterial families and ‘‘others.’’ Because univariable
regression models showed varying and mainly nonlinear associations, we
included month as an indicator variable for both exposure variables, age and
season, in the model. Results are represented as coefficients with 95% CIs and
P values. Analyses were performed with STATA version 12.0 software for
Windows (STATA Corp, College Station, Tex).
RESULTS
Study population and sample processing
A total of 1068 nasal swabs were collected. After exclusion of
low-quality swabs and those obtained during respiratory tract
infection or antibiotic therapy, 872 samples from 47 infants were
included in the final analysis (Fig 1). This corresponds to 19
(range, 11-25) swabs per infant and resulted in 1,096,703
(mean 6 SD, 1258 6 952) high-quality sequence reads. Infants
were considered healthy at the time of sampling. All infants
were breast-fed for a mean 6 SD duration of 8.9 6 2.6 months.
Forty-one study infants obtained 2 doses of pneumococcal
conjugate vaccine within the first year of life.22 Detailed informa-
tion on the study population is listed in Table I and Table E1 in this
article’s Online Repository at www.jacionline.org.
Dynamics of bacterial density and diversity
Bacterial density increased within the first year of life, which
was best modeled by an exponential fit (R25 0.95; Fig 2, A, and
see Table E2 in this article’s Online Repository at www.jacionline.org). In contrast, no seasonal trends were detected for
bacterial density (Fig 2, B). This was confirmed by using the
multivariable regression model (see Table E3 in this article’s
Online Repository at www.jacionline.org).
The SDI, which is based on operational taxonomic units of 97%
sequence identity, decreased exponentially by age and was
lowest at the last month of the first year of life (R2 5 0.73;
Fig 2, C, and see Table E4 in this article’s Online Repository at
A B
C D
FIG 2. Bacterial density and SDI values representing means and 95% CIs. Lines are shown if R2 values are
greater than 0.4. Best fits are indicated. A and B, There is an exponential association of bacterial density by
age (R25 0.95; Fig 2, A); however, there was no trend of SDI values by season (Fig 2, B). C and D, SDI values
decreased exponentially by age (R2 5 0.73; Fig 2, C) and increased in late summer (Fig 2, D).
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late summermonths was found (August, September, and October;
Fig 2, D, and see Table E4). We did not observe significant
differences for SDI values between vaccinated (n 5 41) and
unvaccinated (n 5 7) infants at ages of 2 and 4 months (first
and second dose of pneumococcal vaccine, respectively).
b Diversity: Jaccard dissimilarity measurements
The composition of samples within different time intervals
ranging from 2 to 44 weeks was pairwise compared to investigate
the dissimilarity of the microbiota. Dissimilarity increased
exponentially with increasing time interval (R2 5 0.97; Fig 3,
A), suggesting a higher stability over a short time period. The
time interval of 2 weeks was then chosen to investigate the
influence of age and season on the dissimilarity of the microbiota.
Within-subject dissimilarity was consistently lower than
between-subject dissimilarity within the first year of life (Fig 3,
B). This suggests a distinct personalized microbiota throughout
the first year of life.
Also, this stability was observed during seasonal changes,
except in the month of July, when the within-subject dissimilarity
was not significantly different from the between-subject
dissimilarity (P5 .17, multiple t tests; Fig 3, C). Thus the micro-
biota is most distinct and individualized during thewinter months.
b Diversity: Whole microbial community
comparison by using nMDS
Next, nMDS analyses were used as the ordination method for
whole microbial community comparison. These analyses allowedinvestigation of the phylogenetic variation among all samples
according to age and season. Significant differences in the second
and third months of life were found (P 5 .001 and .002,
respectively; Fig 4, A), indicating a distinctly different microbiota
at this age. Regarding seasonal changes, we observed the months
of December, January, February, and March, which are opposite
to July and August (Fig 4, B). Significant differences were shown
for March, August, and October (P 5 .04, .01, and .02,
respectively). This suggests distinctly different microbiota
profiles for the summer and winter months.Dynamics of bacterial families
The dynamics of the 5 most abundant bacterial
families (Moraxellaceae, Streptococcaceae, Corynebacteriaceae,
Pasteurellaceae, and Staphylococcaceae) and all remaining
families (‘‘others’’) showed a heterogeneous picture for both
age and season.
Streptococcaceae showed no clear trend by age (Fig 5, A),
whereas the opposite was found for Moraxellaceae, Corynebac-
teriaceae, Pasteurellaceae, Staphylococcaceae, and ‘‘others’’
(Fig 5, A-C). These trends by age were best modeled by
exponential functions (see Table E2). Regarding seasonality,
Streptococcaceae, Moraxellaceae, and Staphylococcaceae
showed no clear trend (Fig 5, D and E). In contrast, the
Pasteurellaceae family was more abundant in the winter months,
whereas the opposite was true for Corynebacteriaceae and
‘‘others’’ (Fig 5, E and F). These seasonal trends were
best modeled by using a nonlinear polynomial function (see
Table E2). The multivariable models confirmed that associations
AB
C
FIG 3. Jaccard dissimilarity measurements. A, Exponentially increasing
dissimilarity by increasing time intervals between samples (R2 5 0.97).
Shown are mean values, the 95% prediction band, and the line
indicating best fit. B, There is consistently lower within-subject than
between-subject dissimilarity of samples in 2-week intervals for the first
12 months of age (means and 95% CIs are indicated). C, There was no
significant difference in within-subject and between-subject dissimilarity
in July (P 5 .17, multiple t tests), but differences were significant for all
other months (means and 95% CIs are indicated).
FIG 4. Weighted b diversities represented by using nMDS. Arrows indicate
clustering of samples by age and season. Significance is indicated in red.
A, There is a significant difference by age at months 2 and 3 (‘‘adonis’’
function of R; P 5 .001 and .002, respectively). B, There is a significant
difference by season for March, August, and October (‘‘adonis’’ function
of R; P 5 .04, .01, and .02, respectively).
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other (see Tables E5-E10 in this article’s Online Repository at
www.jacionline.org).DISCUSSION
This prospective cohort study includes high-quality data of 872
nasal swabs from 47 unselected healthy infants and describes
dynamic changes of the upper respiratory tract microbiota within
the first year of life.
Our results showed an increasing bacterial density, which is
opposed by a decreasing SDI value, by age. This indicates thedevelopment of a distinct microbiota profile toward the end of the
first year of life. In addition, we found an increasing dissimilarity
of the microbiota with an increasing time interval between
sampling dates. Also, within-subject dissimilarity was
consistently lower than that between subjects, indicating a
personalized nasal microbiota. Furthermore, there were distinct
bacterial compositions at age 2 to 3 months compared with the
following months. The same was true for the microbiota
composition in summer compared with winter months.
A consistently lower within-subject dissimilarity than between
subjects was also recently shown in a microbiome study at
different body sites.23 Thus a subject’s microbiota is more stable
compared with the microbiota of a study population over age and
season. This stability might be a result of host-environment
equilibrium. If true, the individual microbiota can be considered
a ‘‘fingerprint’’ biomarker, which could be used for research in
future large cross-sectional or longitudinal trials investigating
immune and asthma development.
Although this is the first study on the dynamics of the nasal
microbiota in healthy infants within the first year of lifewith such a
dense sampling, comparable studies were performed on the
infant’s gut microbiota. In contrast to our findings, a gradual
increase in microbial diversity by age was shown.24 However,
superimposed onto these findings are the effects of certain life
A B C
D E F
FIG 5. Relative abundance of bacterial families (means and 95%CIs). Lines indicate R2 values of greater than
0.4. Best fits are indicated. A, Regarding age, Moraxellaceae levels exponentially increased (R2 50.59),
but there were no associations for Streptococcaceae. B, Exponential association for Staphylococcaceae
(R2 5 0.94) and Pasteurellaceae (R2 5 0.57). C, Exponential decay for Corynebacteriaceae (R2 5 0.96)
and ‘‘others’’ (R2 5 0.44). D, Regarding season, there were no associations for Moraxellaceae and Strepto-
coccaceae. E and F, Polynomial association for Pasteurellaceae (R2 5 0.62; Fig 5, E), Corynebacteriaceae
(R2 5 0.45), and ‘‘others’’ (R2 5 0.58; Fig 5, F).
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directly affect the diversity of the gut microbiota.24-26 Thus
findings of density and diversity in our study suggest a diverse
and transient colonization in the first few months of life. Also,
by using nMDS plots, a distinct clustering of the second and third
months of age apart from the following months was observed. In a
similar vein a recent study demonstrated an association between
the colonization of the upper airways by bacterial pathogens at
the age of 6 months and cough and wheezing episodes within
the first year of life.27 An immune response induced by the
microbiota was suggested, which activates and possibly
influences maturation of the adaptive immune system.28
Therefore we hypothesize that the nasal microbiota is sensitive
to disturbances, especially in the first months of life. The rather
high relative abundance of Corynebacteriaceae and Staphylococ-
caceae in the first few months resembles the microbial
composition found on the skin in this age group.29 Therefore we
assume that the nasal microbiota is similar to that on the skin in
the first months of life, probably because of the close contact of
the infant to the mother’s skin during breast-feeding. The infant
later had a ‘‘characteristic’’ respiratory tract microbiota over
time. It should be noted that similar studies were performed in
The Netherlands.30,31 In particular, the authors of those studies
discovered higher levels of Staphylococcus and Corynebacterium
in the nasopharynx regardless of feeding type at the age of 6 weeks
compared with 6 months.30 They hypothesized that this might be
explained by environmental encounters. Staphylococcaceae andCorynebacteriaceae levels were also clearly increased in the first
2 to 4 months of life in our study, which caused us to hypothesize
that our findings from Switzerland are also applicable to infants in
different countries with a similar climate. Moraxellaceae and
Streptococcaceae showed the highest relative abundance per
sample, which accords with previous studies in which these
families were found as part of the healthy nasopharyngeal
microbiota.11,13,14 Earlier studies with conventional culture
methods also showed a high prevalence of Moraxellaceae in
nasopharyngeal samples, which confirms the results obtained by
using next-generation sequencing methods.32,33
Regarding seasonal changes, we found an increase of
Corynebacteriaceae and ‘‘others’’ in the summer months. In
contrast, Pasteurellaceae were more abundant during winter. This
was also expected for Moraxellaceae and Streptococcaceae
because a previous study showed a peak colonization incidence
of M catarrhalis and H influenzae in healthy children in
fall/winter and winter/spring, respectively.34 Associations be-
tween S pneumoniae, H influenzae, and M catarrhalis coloniza-
tion and the presence of multiple respiratory tract viruses in the
nasopharynx of otherwise healthy children were also found.35
This suggests an outgrowth of potential pathogens, which is prob-
ably driven by the presence of winter viruses. In line with this hy-
pothesis, a recent study in a mouse model showed a decrease in
microbial diversity on introduction of S pneumoniae in the upper
respiratory tract and a temporary dominance of pneumococci in
the microbiota.36 However, because the Moraxellaceae and
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as commensal, species, we assume inverse seasonal patterns for
these species, which would result in their cancelling each other
out.
Seasonal changes were also observed in theb diversity analysis
by using nMDS plots, in which samples obtained in warmer
months group differently to samples from colder months. In a
recent study a causal role of winter viral infection during
infancy and early childhood asthma was found, wherein
infants born approximately 4 months before the winter virus
peak carried the highest risk.37 This supports our finding of
decreased diversity in thewintermonths, as well as our hypothesis
that infants experience a higher sensitivity to disturbances in the
first months of life, as discussed above. Also, this underlines the
importance of both age and season on the dynamics of the
microbiota.
Our study has some major strengths. We performed a dense
sampling of 48 infants within the first year of life, resulting in
more than 800 analyzed samples. Such detailed longitudinal data
are not yet available but are necessary to illustrate the dynamics of
the microbiota over age and season. In fact, we believe that an
even denser sampling would be necessary to better understand the
dynamic changes of the microbiota. In a preliminary analysis we
looked at the microbiota from 2 consecutive nasal swabs of 10
infants taken within 3 hours. First results showed lower
within-subject dissimilarity of these samples compared with the
shortest time interval in this study (2 weeks). An additional
strength of this study is the fact that the infants’ dates of birth are
equally distributed throughout the year, minimizing the
misinterpretation of results based on skewed distribution of
months of birth. We also only included infants who were
breast-fed, and all were chosen from a rather homogeneous
sampling area. This is an advantage because it makes this study
less prone to other influencing factors, such as climate and
ethnicity.
However, there are some limitations of this study. Because the
nasal cavities are not yet fully developed in infants, taking
nasopharyngeal swabs bears the risk of trauma or perforation.
Therefore we performed nasal sampling and considered nasal
swabs as representative of the upper respiratory tract microbiota,
as was recently shown.10 Rapola et al38 also demonstrated that
isolation rates of the otitis media pathogens S pneumoniae and
H influenzae do not differ between nasal and nasopharyngeal
swabs. In addition, the nasal swabs were taken by the parents of
the study infants, and thus we cannot exclude a potential sampling
bias because an inadequately obtained swab possibly interferes
with sample processing, particularly given that wewere analyzing
low-density communities.17 Therefore for quality control, we
excluded all samples containing a bacterial DNA concentration
of less than 1 pg/mL or with greater than 5% sequences
being identical to those of a negative control, as recently
recommended.39 We also omitted samples at the time of infection
but not 2 or more weeks after. Preliminary analyses investigating
Jaccard dissimilarity shortly before, during, and after infection
revealed that this is a justified approach. However, more samples
and a different study design are needed to investigate the effect of
infection on the microbiota composition.
Finally, we analyzed the microbiota data of this study in a
pooled way rather than for each infant individually. This might
mask considerable changes within a subject’s microbiota.
Because there are many host and environmental factors thatmight explain these changes, analyses of these factors would go
beyond the scope of this study. Mean values are likely to reduce
the effect of such factors, including the occasional inadequate
sampling, and should therefore reveal the influence of age and
season more accurately.
In conclusion, in this study we were able to demonstrate the
dynamics of the nasal microbiota in healthy infants within the first
year of life. Furthermore, we demonstrated the need for age and
seasonal variability to be taken into account when assessing
microbiota data. Interestingly, a relative uniqueness of a subject’s
microbiota was found, which is most pronounced in the winter
months (ie, a personalized microbiota). Overall, these data serve
as essential baseline information for intervention studies in
infants and are necessary for future investigation of the influence
of disease, environmental, and/or host factors on a subject’s
microbiota.
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Key messages
d Nasal microbiota shows higher intraindividual than inter-
individual similarity.
d Dissimilarity of the microbiota increases with increasing
time intervals between samples.
d There is a distinct bacterial composition in the first 3
months of life.
d Age and seasonality are major factors driving the dy-
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TABLE E1. Overview of study infants and numbers of swabs
ID Date of birth
Pneumococcal vaccine*
Included swabs
Excluded swabs
TotalFirst dose Second dose Infection/antibiotics ‘‘Others’’y
1 02.2010 9.7 17.7 16 1 5 22
2 04.2010 8.7 17.9 17 0 8 25
3 04.2010 16.4 27.1 20 1 3 24
4 04.2010 9.7 18.6 23 0 0 23
5 05.2010 10.4 21.6 15 1 1 17
6 06.2010 8.6 14.6 17 0 5 22
7 06.2010 8.4 18.0 15 0 9 24
8 07.2010 9.0 17.7 22 3 0 25
9 07.2010 9.6 18.6 18 0 4 22
10 07.2010 20 1 1 22
11 07.2010 18 1 2 21
12 07.2010 8.3 17.3 21 0 2 23
13 08.2010 19 0 1 20
14 08.2010 10.0 20.0 19 1 1 21
15 08.2010 9.6 19.7 18 1 5 24
16 09.2010 9.7 19.9 22 0 2 24
17 09.2010 8.1 18.1 19 0 0 19
18 09.2010 9.0 18.0 16 2 6 24
19 10.2010 9.3 19.6 13 0 10 23
20 10.2010 8.6 18.0 11 0 5 16
21 10.2010 8.0 17.0 14 0 7 21
22 11.2010 15 1 7 23
23 11.2010 9.7 18.1 23 1 0 24
24 11.2010 0 0 21 21
25 12.2010 9.3 22 0 2 24
26 12.2010 10.3 20.4 16 0 4 20
27 01.2011 8.4 17.7 19 1 1 21
28 01.2011 31.0 40.1 18 0 6 24
29 01.2011 9.3 9.3 16 0 7 23
30 02.2011 8.9 18.7 15 1 5 21
31 03.2011 8.9 17.7 17 0 8 25
32 03.2011 10.6 19.6 20 0 3 23
33 03.2011 9.7 18.0 19 0 3 22
34 06.2011 10.9 18.9 17 0 0 17
35 07.2011 10.3 17.4 21 1 0 22
36 10.2011 9.7 18.7 23 0 0 23
37 10.2011 15 0 6 21
38 12.2011 9.9 18.3 21 0 2 23
39 04.2012 9.9 19.9 12 0 12 24
40 04.2012 8.7 17.1 19 1 4 24
41 05.2012 9.6 15.6 20 0 2 22
42 08.2012 9.4 17.4 20 0 2 22
43 10.2012 10.6 18.7 22 1 0 23
44 01.2013 8.0 17.0 25 0 0 25
45 01.2013 8.6 17.9 21 0 1 22
46 02.2013 9.7 19.0 19 0 2 21
47 05.2013 12.7 19.3 21 1 1 23
48 07.2013 9.0 20.0 23 0 0 23
Total 872 20 176 1068
*Indicated is the number of weeks after birth. The recommended vaccination schedule for pneumococcal conjugate vaccine is 2, 4, and 11 to 15 months.E1 None of the study infants
received the third dose before the 12th month of life.
Other reasons for exclusion were no amplification or less than 1 ng/mL PCR product, less than 70 sequence reads, or greater than 5% sequence reads identical to the negative
control sample.
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TABLE E2. Regression analyses
Outcome variable
Age Season
Exponential fit* Polynomial fit
Bacterial density 0.95 0.05
Y 5 9.9 1 (47.7 2 9.9) * (1-exp[-0.1 * X]) Y 5 34.3 2 0.4 * X 1 0.02 * X2
SDI 0.73 0.18
Y 5 0.8 * exp(20.2 * X) 1 0.1 Y 5 1.2 1 0.004 * X 1 0.001 * X2
Streptococcaceae Not converged 0.08
Y 5 20.7 2 0.1 * X 1 0.02 * X2
Moraxellaceae 0.59 0.3
Y 5 2.5 1 (38.1 2 2.5) * (12exp[20.5 * X]) Y 5 43.2 2 2.6 * X 1 0.2 * X2
Staphylococcaceae 0.94 0.32
Y 5 26.5 * exp(20.3 * X) 1 0.1 Y 5 4.8 2 0.4 * X 1 0.06 * X2
Corynebacteriaceae 0.96 0.45
Y 5 17.8 * exp(20.2 * X) 2 0.9 Y 5 0.06 1 1.5 * X 2 0.1 * X2
Pasteurellaceae 0.57 0.62
Y 5 1.5 1 (14.2 2 1.5) * (1-exp[20.1 * X]) Y 5 10.9 2 2.1 * X 1 0.2 * X2
‘‘Others’’ 0.44 0.58
Y 5 21.8 1 (62.4 2 21.8) * (1-exp[20.03 * X]) Y 5 20.3 1 3.7 * X 2 0.3 * X2
Jaccard dissimilarity 0.97
Y 5 0.62 1 (0.84 2 0.62) * (1-exp[20.05 * X])
Data were derived from regression analysis. Shown is the goodness of fit as R2 values for all outcome variables according to age and season. If the R2 value if greater than 0.4, the
corresponding equation of the best fit is indicated in boldface.
*Additionally, linear regression was fitted for age; however, this was found to be inferior to the exponential fit for all outcome variables.
Shown is goodness of fit according to the time interval Dt in weeks.
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TABLE E3. Adjusted analysis of bacterial density
Bacterial density
Adjusted analysis
Coefficient 95% CI P value
Age (mo)
3 1.3 26.4 to 9.0 .7
4 6.5 21.4 to 14.4 .1
5 8.6 1.0 to 16.3 <.05
6 10.2 2.2 to 18.1 <.05
7 13.1 5.3 to 20.9 <.05
8 18.7 10.9 to 26.6 <.05
9 18.4 10.4 to 26.4 <.05
10 18.4 10.6 to 26.3 <.05
11 16.5 8.6 to 24.5 <.05
12 21.5 13.5 to 29.6 <.05
Month of year
February 20.8 29.0 to 7.4 .9
March 20.3 28.3 to 7.6 .9
April 1.0 27.1 to 9.1 .8
May 20.5 28.5 to 7.4 .9
June 0.1 28.1 to 8.2 1.0
July 20.1 28.3 to 8.1 1.0
August 21.2 29.4 to 7.0 .8
September 22.6 210.8 to 5.5 .5
October 27.0 215.0 to 0.9 .1
November 1.1 26.7 to 9.0 .8
December 3.8 24.2 to 11.9 .4
Data are derived from linear regression analysis. Coefficient of adjusted analysis was
used for all variables. Reference variables were age of 2 months and January.
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TABLE E4. Adjusted analysis of SDI values
SDI value
Adjusted analysis
Coefficient 95% CI P value
Age (mo)
3 20.1 20.3 to 0.1 .3
4 20.3 20.6 to 20.1 <.05
5 20.4 20.6 to 20.1 <.05
6 20.2 20.5 to 0.01 .1
7 20.4 20.6 to 20.2 <.05
8 20.3 20.5 to 20.03 <.05
9 20.4 20.7 to 20.2 <.05
10 20.5 20.7 to 20.3 <.05
11 20.4 20.6 to 20.2 <.05
12 20.6 20.8 to 20.3 <.05
Month of year
February 0.0 20.2 to 0.2 1.0
March 20.1 20.4 to 0.1 .3
April 20.1 20.4 to 0.1 .3
May 20.1 20.4 to 0.1 .2
June 20.1 20.4 to 0.1 .3
July 0.1 20.2 to 0.3 .7
August 0.2 20.1 to 0.4 .2
September 0.2 20.05 to 0.4 .1
October 0.2 20.05 to 0.4 .1
November 0.0 20.2 to 0.2 .9
December 20.1 20.3 to 0.2 .5
Data are derived from linear regression analysis. Coefficient of adjusted analysis was
used for all variables. Reference variables were age of 2 months and January.
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TABLE E5. Adjusted analysis of the relative abundance of
Streptococcaceae
Streptococcaceae
Adjusted analysis
Coefficient 95% CI P value
Age (mo)
3 0.1 27.2 to 7.5 1.0
4 0.0 27.5 to 7.5 1.0
5 0.3 26.9 to 7.6 .9
6 0.1 27.5 to 7.7 1.0
7 22.5 29.9 to 4.9 .5
8 0.5 26.9 to 8.0 .9
9 2.2 25.5 to 9.8 .6
10 23.4 210.8 to 4.1 .4
11 23.5 211.0 to 4.0 .4
12 24.6 212.2 to 3.1 .2
Month of year
February 2.9 24.9 to 10.7 .5
March 0.5 27.1 to 8.0 .9
April 4.9 22.8 to 12.5 .2
May 1.9 25.7 to 9.4 .6
June 1.3 26.4 to 9.1 .7
July 2.0 25.9 to 9.8 .6
August 20.2 28.0 to 7.5 1.0
September 0.8 27.0 to 8.5 .8
October 7.2 20.3 to 14.8 .1
November 5.6 21.9 to 13.1 .1
December 20.6 28.3 to 7.0 .9
Data are derived from linear regression analysis. Coefficient of adjusted analysis was
used for all variables. Reference variables were age of 2 months and January.
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TABLE E6. Adjusted analysis of the relative abundance of
Moraxellaceae
Moraxellaceae
Adjusted analysis
Coefficient 95% CI P value
Age (mo)
3 3.5 26.2 to 13.2 .5
4 7.5 22.4 to 17.4 .1
5 16.2 6.6 to 25.8 <.05
6 14.4 4.5 to 24.4 <.05
7 13.5 3.7 to 23.3 <.05
8 12.5 2.7 to 22.4 <.05
9 7.0 23.1 to 17.1 .2
10 17.0 7.2 to 26.9 <.05
11 14.2 4.3 to 24.2 <.05
12 17.6 7.5 to 27.7 <.05
Month of year
February 4.0 26.3 to 14.3 .4
March 2.9 27.1 to 12.9 .6
April 24.4 214.4 to 5.7 .4
May 0.0 29.9 to 9.9 1.0
June 1.8 28.4 to 12.0 .7
July 26.2 216.6 to 4.1 .2
August 27.0 217.3 to 3.3 .2
September 21.7 212.0 to 8.5 .7
October 211.3 221.2 to 21.4 <.05
November 23.4 213.2 to 6.5 .5
December 3.6 26.5 to 13.7 .5
Data are derived from linear regression analysis. Coefficient of adjusted analysis was
used for all variables. Reference variables were age of 2 months and January.
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TABLE E7. Adjusted analysis of the relative abundance of
Staphylococcaceae
Staphylococcaceae
Adjusted analysis
Coefficient 95% CI P value
Age (mo)
3 23.5 28.5 to 1.5 .2
4 26.9 212.0 to 21.8 <.05
5 28.9 213.9 to 24.0 <.05
6 210.1 215.2 to 24.9 <.05
7 212.3 217.3 to 27.2 <.05
8 213.4 218.5 to 28.3 <.05
9 214.4 219.6 to 29.2 <.05
10 213.5 218.6 to 28.4 <.05
11 212.9 218.1 to 27.8 <.05
12 213.5 218.7 to 28.3 <.05
Month of year
February 22.3 27.6 to 3.0 .4
March 23.7 28.9 to 1.5 .2
April 20.1 25.3 to 5.1 1.0
May 0.4 24.7 to 5.5 .9
June 20.9 26.1 to 4.4 .7
July 0.9 24.5 to 6.2 .8
August 20.1 25.4 to 5.2 1.0
September 25.0 210.3 to 0.3 .1
October 2.8 22.3 to 7.9 .3
November 1.8 23.3 to 6.9 .5
December 2.1 23.2 to 7.3 .4
Data are derived from linear regression analysis. Coefficient of adjusted analysis was
used for all variables. Reference variables were age of 2 months and January.
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TABLE E8. Adjusted analysis of the relative abundance of
Pasteurellaceae
Pasteurellaceae
Adjusted analysis
Coefficient 95% CI P value
Age (mo)
3 0.8 24.1 to 5.7 .7
4 0.2 24.8 to 5.2 .9
5 0.0 24.9 to 4.8 1.0
6 3.1 21.9 to 8.2 .2
7 1.5 23.5 to 6.4 .6
8 3.2 21.7 to 8.2 .2
9 7.1 2.0 to 12.2 <.05
10 3.8 21.1 to 8.8 .1
11 5.0 20.1 to 10.0 .1
12 4.1 21.0 to 9.2 .1
Month of year
February 25.0 210.2 to 0.2 .1
March 24.3 29.4 to 0.7 .1
April 25.5 210.6 to 20.4 <.05
May 27.8 212.8 to 22.8 <.05
June 25.0 210.2 to 0.1 .1
July 27.8 213.0 to 22.6 <.05
August 26.0 211.1 to 20.8 <.05
September 23.0 28.1 to 2.2 .3
October 22.4 27.4 to 2.6 .4
November 23.3 28.3 to 1.7 .2
December 22.7 27.8 to 2.4 .3
Data are derived from linear regression analysis. Coefficient of adjusted analysis was
used for all variables. Reference variables were age of 2 months and January.
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TABLE E9. Adjusted analysis of the relative abundance of
Corynebacteriaceae
Corynebacteriaceae
Adjusted Analysis
Coefficient 95% CI P value
Age (mo)
3 23.0 26.3 to 0.2 .1
4 24.1 27.4 to 20.8 <.05
5 26.1 29.3 to 22.9 <.05
6 26.4 29.9 to 23.0 <.05
7 26.4 29.7 to 23.1 <.05
8 28.3 211.6 to 25.0 <.05
9 29.6 213.0 to 26.3 <.05
10 29.8 213.1 to 26.5 <.05
11 29.4 212.7 to 26.0 <.05
12 210.0 213.4 to 26.6 <.05
Month of year
February 0.1 23.3 to 3.5 1.0
March 0.8 22.6 to 4.1 .7
April 2.0 21.4 to 5.3 .3
May 1.4 22.0 to 4.7 .4
June 2.8 20.6 to 6.2 .1
July 0.7 22.8 to 4.1 .7
August 4.3 0.9 to 7.7 <.05
September 4.5 1.1 to 8.0 <.05
October 0.7 22.6 to 4.0 .7
November 20.3 23.6 to 3.0 .9
December 20.1 23.5 to 3.2 .9
Data are derived from linear regression analysis. Coefficient of adjusted analysis was
used for all variables. Reference variables were age of 2 months and January.
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TABLE E10. Adjusted analysis of the relative abundance of
other bacterial families
Other bacterial families
Adjusted analysis
Coefficient 95% CI P value
Age (mo)
3 2.3 26.7 to 11.3 .6
4 3.3 25.9 to 12.5 .5
5 21.4 210.4 to 7.5 .8
6 21.0 210.3 to 8.3 .8
7 6.6 22.6 to 15.7 .2
8 5.4 23.8 to 14.6 .2
9 7.9 21.5 to 17.3 .1
10 6.0 23.2 to 15.1 .2
11 6.4 22.8 to 15.7 .2
12 6.5 22.9 to 15.9 .2
Month of year
February 0.3 29.3 to 9.9 1.0
March 4.0 25.3 to 13.4 .4
April 3.0 26.4 to 12.4 .5
May 4.0 25.3 to 13.2 .4
June 20.5 210.0 to 9.0 .9
July 10.6 0.9 to 20.2 <.05
August 8.9 20.7 to 18.4 .1
September 4.3 25.2 to 13.9 .4
October 2.9 26.3 to 12.2 .5
November 20.3 29.5 to 8.9 .9
December 22.0 211.4 to 7.4 .7
Data are derived from linear regression analysis. Coefficient of adjusted analysis was
used for all variables. Reference variables were age of 2 months and January.
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